Cancer Immunotherapy utilizing a novel receptor for Programmed cell death-1 ligand 2

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1113888

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

Immuno-modulators utilize the patient’s own immune system to eliminate or slow the growth of cancerous cells. We have identified a novel immuno-modulator which could be a significant player in immune-modulation therapy for the treatment of cancer. We will use the development grant to develop a product which has significant potential to be the next generation treatment for cancer.

Funded Activity Details

Start Date: 01-01-2016

End Date: 01-01-2017

Funding Scheme: Development Grants

Funding Amount: $577,857.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Tumour Immunology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

cancer immunology | cancer immunotherapy | cellular interactions | immune evasion | immune modulation

Related Links